Skip to main content

Table 3 Symptom severity, duration and medication use from diary

From: Pelargonium sidoides root extract for the treatment of acute cough due to lower respiratory tract infection in adults: a feasibility double-blind, placebo-controlled randomised trial

  Liquid Kaloba® (n = 31) Liquid placebo (n = 26) Tablet Kaloba® (n = 21) Tablet placebo (n = 22) All participants
Last day of any moderately bad symptoms1 7 (4,15) 12 (4,17) 9 (5,13) 9 (4,15) 9 (4,14)
First day of no moderately bad symptoms2 7 (4,8) 8 (4,13) 6.5 (4,11) 8 (5,14.5) 7 (4,11)
Last day of any symptoms 9 (6,17) 13.5 (7,19) 11 (8,14) 12.5 (8,24) 11 (7,17.5)
First day of no symptoms 10 (6,12) 12 (6,17) 7 (6,12) 11 (8,15) 9 (6,14)
Moderately bad symptoms resolved by day 7? 17/31 (54.8%) 9/26 (34.6%) 9/21 (42.9%) 10/22 (45.5%) 45/97 (46.4%)
Moderately bad symptoms resolved by day 14? 23/31 (74.2%) 17/26 (65.4%) 18/21 (85.7%) 16/22 (72.7%) 74/100 (74.0%)
All symptoms resolved by day 7? 10/31 (32.3%) 7/26 (26.9%) 4/21 (19.1%) 5/22 (22.7%) 26/100 (26.0%)
All symptoms resolved by day 14? 22/31 (71.0%) 15/26 (57.7%) 16/21 (76.2%) 14/22 (63.6%) 67/100 (67.0%)
Antibiotics started? 15/31 (48.4%) 6/26 (23.1%) 9/21 (47.6%) 11/22 (50.0%) 41/100 (41.0%)
Days to first dose of antibiotics in those who reported taking them (median, interquartile range) 1 (1,1) 1 (1,8) 1 (1,9) 1 (1,6) 1 (1,4)
  1. 1. The last day of moderately bad symptoms, defined as a score of 3 or more, based on all symptoms recorded in the patient diary
  2. 2. The first day without any moderately bad symptoms, a score of 3 or more, based on all symptoms recorded in the patient diary. As severity of symptoms fluctuates, patients may subsequently experience further days with moderately bad symptoms
\